Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Rating of “Buy” by Brokerages

Stoke Therapeutics, Inc. (NASDAQ:STOK) has been given an average recommendation of “Buy” by the seven ratings firms that are presently covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $23.20.

A number of equities research analysts have weighed in on the company. HC Wainwright reduced their price objective on Stoke Therapeutics from $47.00 to $35.00 and set a “buy” rating for the company in a research note on Wednesday, May 14th. Chardan Capital reiterated a “buy” rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, April 9th. Finally, Cantor Fitzgerald upgraded Stoke Therapeutics to a “strong-buy” rating in a research note on Wednesday, May 14th.

Insider Transactions at Stoke Therapeutics

In other news, Director Edward M. Md Kaye sold 10,382 shares of the company’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the sale, the director now owns 148,253 shares in the company, valued at $1,285,353.51. This represents a 6.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Barry Ticho sold 3,884 shares of the company’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $33,674.28. Following the sale, the insider now owns 63,962 shares of the company’s stock, valued at $554,550.54. This trade represents a 5.72% decrease in their position. The disclosure for this sale can be found here. Insiders sold 24,748 shares of company stock worth $225,687 over the last 90 days. 11.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Stoke Therapeutics

Several large investors have recently modified their holdings of STOK. Wellington Management Group LLP grew its holdings in Stoke Therapeutics by 0.9% during the first quarter. Wellington Management Group LLP now owns 135,960 shares of the company’s stock worth $904,000 after acquiring an additional 1,148 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Stoke Therapeutics by 5.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company’s stock worth $162,000 after acquiring an additional 1,149 shares during the period. Bank of New York Mellon Corp grew its holdings in Stoke Therapeutics by 1.4% during the fourth quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company’s stock worth $1,028,000 after acquiring an additional 1,330 shares during the period. Graham Capital Management L.P. grew its holdings in Stoke Therapeutics by 8.5% during the fourth quarter. Graham Capital Management L.P. now owns 18,634 shares of the company’s stock worth $206,000 after acquiring an additional 1,453 shares during the period. Finally, Gilder Gagnon Howe & Co. LLC grew its holdings in Stoke Therapeutics by 2.0% during the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 92,546 shares of the company’s stock worth $1,021,000 after acquiring an additional 1,791 shares during the period.

Stoke Therapeutics Stock Down 0.1%

Shares of STOK opened at $11.13 on Thursday. The stock has a 50 day moving average price of $8.86 and a 200 day moving average price of $9.64. The company has a market capitalization of $607.66 million, a price-to-earnings ratio of -5.30 and a beta of 1.09. Stoke Therapeutics has a 52-week low of $5.35 and a 52-week high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The firm had revenue of $22.61 million during the quarter, compared to the consensus estimate of $4.20 million. On average, equities analysts anticipate that Stoke Therapeutics will post -2.01 EPS for the current fiscal year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.